The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

Figure 5

Results of Monte Carlo simulation of incremental cost and effectiveness scatter plot of CERA versus EpoB, based on 50000 random iterations of cost-effectiveness model.